Article Sidebar

Submitted
May 13, 2021
Published
May 13, 2021
Download
PDF
Statistic
Read Counter : 129 Download : 65

Main Article Content

Abstract

Simarouba glauca a member of the Simaroubaceae family, is used in antimicrobial and insecticidal activity, antidysentric, antiherpetic, antihelminthic and antiprotozoal activities, but according to the best of our knowledge there is no scientific detailed report on antioxidant, haemolytic and thrombolytic activities. The purpose of the present study is to investigate the acute oral toxicity and anti-ulcer profile of the Chloroform Extract of Simarouba glauca (CSG) extract in albino rats. No toxicity of extract up to 2000 mg/kg body weight orally as per OECD guidelines No.423. CSG at the doses of 200 and 400 mg/kg body weight orally was administered to evaluate anti- ulcer activity by using Ethanol and indomethacin, induced gastric ulcer models in Albino rats. Chloroform extract of Simarouba glauca dose dependent inhibition in ethanol induced gastric lesions, causing 82.63 % protection at 400 mg/kg, and 53.48 % protection at 200 mg/kg, CSG dose dependent inhibition in indomethacin induced gastric lesions, causing 62.65 % protection at 400 mg/kg and 54.86 % protection at 200 mg/kg, All the results are found to be statistically significant (p≤0.05). Hence we suggest that Chloroform Extract of the leaves of Simarouba glauca was able to decrease the acidity and to increase the mucosal defense in the gastric areas, thereby justifying its use as an antiulcerogenic agent.

Keywords

Simarouba glauca Anti-ulcer activity Ethanol Indomethacin

Article Details

How to Cite
Dr.Shankara sharma, & N.Sriram. (2021). Anti-Ulcer activity of Simarouba glauca against Ethanol and Indomethacin induced ulcer in rats. International Journal of Research in Pharmacology & Pharmacotherapeutics, 3(2), 85-89. https://doi.org/10.61096/ijrpp.v3.iss2.2014.85-89
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] Nash J, Lambert L, Deakin M. Histamine H2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use. Drugs, 47, 1994, 862–871.
  2. [2] Hoogerwerf WA, Pasricha PJ. Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal reflux disease. In: Hardman JG, Limbird LE, Goodman Gilaman A. (Eds.), The Pharmacological Basis of Therapeutics, tenth ed. Mc Graw-Hill, New York, 2001, pp. 1005–1019.
  3. [3] Valle DL. Peptic ulcer diseases and related disorders. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. (Eds.), Harrison’s Principles of Internal Medicine, vol. 16. McGraw-Hill, New York, 2005, pp. 1746–1762.
  4. [4] Manonmani S, Viswanathan VP, Subramanian S, Govindasamy S. Biochemical studies on the antiulcerogenic activity of cauvery 100, an ayurvedic formulation in experimental ulcers. Indian Journal of Pharmacology, 27, 1995, 101–105.
  5. [5] Muganza, D., et al. "In vitro antiprotozoal and cytotoxic activity of 33 ethonopharmacologically selected medicinal plants from Democratic Republic of Congo." J Ethnopharmacol. 2012 May 7;141(1):301-8.
  6. [6] Garcia, M., et al. "Activity of Cuban Plants Extracts against Leishmania amazonensis." ISRN Pharmacol. 2012;2012:104540.
  7. [7] Francois, G., et al. ”Antimalarial and cytotoxic potential of four quassinoids from Hannoa chlorantha and Hannoa klaineana, and their structure-activity relationships.” Int. J. Parasitol. 1998; 28(4): 635-40.
  8. [8] Franssen, F. F., et al. “In vivo and in vitro antiplasmodial activities of some plants traditionally used in Guatemala against malaria.” Antimicrob. Agents Chemother. 1997; 41(7): 1500–3.
  9. [9] Wright, C. W., et al. “Quassinoids exhibit greater selectivity against Plasmodium falciparum than against Entamoeba histoyltica, Giardia intestinalis or Toxoplasma gondii in vitro." J. Eukaryot. Microbiol. 1993; 40(3): 244–46.
  10. [10] Kirby, G. C., et al. “In vitro studies on the mode of action of quassinoids with activity against chloroquine- resistant Plasmodium falciparum.” Biochem. Pharmacol. 1989; 38(24): 4367–74.
  11. [11] O’Neill, M. J., et al. “Plants as sources of antimalarial drugs, Part 6. Activities of Simarouba amara leavess." J. Ethnopharmacol. 1988; 22(2): 183–90.
  12. [12] O’Neill, M. J., et al. “The activity of Simarouba amara against chloroquine-resistant Plasmodium falciparum in vitro." J. Pharm. Pharmacol. 1987; Suppl. 39: 80.
  13. [13] Monjour, I., et al. “Therapeutic trials of experimental murine malaria with the quassinoid, glaucarubinone.” C. R. Acad. Sci. Ill. 1987; 304(6): 129–32.
  14. [14] Trager, W., et al. “Antimalarial activity of quassinoids against chloroquine-resistant Plasmodium falciparum in vitro." Am. J. Trp. Med. Hyg. 1981; 30(3): 531–37.
  15. [15] Duriez, R., et al. “Glaucarubin in the treatment of amebiasis." Presse Med. 1962; 70: 1291.
  16. [16] Spencer, C. F., et al. “Survey of plants for antimalarial activity.” Lloydia 1947; 10: 145–74.
  17. [17] Cuckler, A. C., et al. “Efficacy and toxicity of simaroubidin in experimental amoebiasis.” Fed. Proc. 1944; 8: 284.
  18. [18] Shepheard, S., et al. "Persistent carriers of Entameba histolytica." Lancet 1918: 501.